| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data|
Docs:
|
"SECURITIES PURCHASE AGREEMENT QSAM BIOSCIENCES - COMMON STOCK This Securities Purchase Agreement , between QSAM Biosciences Inc., a Delaware corporation, and the purchaser set forth below , is dated as of the date signed by the Company . The Company and the Purchasers may be referred to individually, as a “Party” and collectively, as the “Parties.” WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act of 1933, as amended , and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Purchasers, and the Purchasers, desires to purchase from the Company, securities of the Company as more fully described in this Agreement . NOW THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,..." |
|
| 08/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/12/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 04/04/2023 |
8-K
| Unregistered Sales of Equity Securities Interactive Data |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Investor presentation |
| 02/14/2023 |
SC 13G/A
| GSB Holdings, Inc. reports a 17.2% stake in QSAM Biosciences, Inc. |
| 01/25/2023 |
8-K
| Investor presentation |
| 01/10/2023 |
8-K
| Quarterly results |
| 11/18/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/06/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 10/06/2022 |
8-K
| Quarterly results |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/04/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 04/01/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/29/2022 |
CERT
| Form CERT - Certification by an exchange approving securities for listing: |
| 03/28/2022 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 03/23/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/10/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 03/09/2022 |
8-K
| Quarterly results |
| 03/04/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/15/2022 |
5
| Piazza C Richard (Executive Chairman) has filed a Form 5 on QSAM Biosciences, Inc. |
| 02/15/2022 |
5
| Baum Douglas R (CEO & Director) has filed a Form 5 on QSAM Biosciences, Inc. |
| 02/15/2022 |
5
| Link David Charles (Director) has filed a Form 5 on QSAM Biosciences, Inc. |
| 02/14/2022 |
5
| Nelson Christopher M. (General Counsel and Director) has filed a Form 5 on QSAM Biosciences, Inc. |
| 02/14/2022 |
5
| Mayersohn Joel David (Director) has filed a Form 5 on QSAM Biosciences, Inc. |
|